Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
UBS
Queensland Health
Medtronic
Farmers Insurance
US Army

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,855,270

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,855,270
Title:Methods and compositions for modulating estrogen receptor mutants
Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
Inventor(s): Hager; Jeffrey J. (San Diego, CA), Joseph; James D. (San Diego, CA), Qian; Jing (San Diego, CA), Smith; Nicholas D. (San Diego, CA), Chow Maneval; Edna (San Diego, CA), Roychowdhury; Debasish F. (San Diego, CA), Friedman; Lori (San Carlos, CA), Sampath; Deepak (San Francisco, CA)
Assignee: GENENTECH, INC. (South San Francisco, CA)
Application Number:14/645,578
Patent Claims:see list of patent claims

Details for Patent 9,855,270

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up GENENTECH, INC. (South San Francisco, CA) 2038-01-11 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up GENENTECH, INC. (South San Francisco, CA) 2038-01-11 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up GENENTECH, INC. (South San Francisco, CA) 2038-01-11 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08 ➤ Sign Up GENENTECH, INC. (South San Francisco, CA) 2038-01-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Teva
Boehringer Ingelheim
Cantor Fitzgerald
Fish and Richardson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.